SCHEMBL1470545

SCHEMBL1470545

CCOC(=O)/C=C1/CCc2ccc(OC)cc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 3/20 0.61
MTNR1A P48039 3/20 0.61
MTNR1B P49286 3/20 0.61
CYP19A1 P11511 5/20 0.49
CYP11B2 P19099 2/20 0.49
MAOB P27338 2/20 0.47
BRD4 O60885 1/20 0.44
MAOA P21397 2/20 0.44
LMNA P02545 2/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ACHE P22303 1/20 0.42
CYP24A1 Q07973 1/20 0.41
CYP26A1 O43174 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MIF P14174 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12749769 1.00 NQO2 (0.61) NQO2MTNR1AMTNR1BCYP19A1CYP11B2
SCHEMBL1470548 1.00 NQO2 (0.61) NQO2MTNR1AMTNR1BCYP19A1CYP11B2
SCHEMBL9290663 0.92 NQO2 (0.53) NQO2MTNR1AMTNR1BCYP19A1CYP11B2
SCHEMBL8514303 0.92 NQO2 (0.53) NQO2MTNR1AMTNR1BCYP19A1CYP11B2
SCHEMBL8514302 0.92 NQO2 (0.53) NQO2MTNR1AMTNR1BCYP19A1CYP11B2
SCHEMBL821438 0.90 NQO2 (0.49) NQO2MTNR1AMTNR1BCYP19A1CYP11B2
SCHEMBL16048803 0.90 NQO2 (0.49) NQO2MTNR1AMTNR1BCYP19A1CYP11B2
SCHEMBL31660644 0.87 NQO2 (0.47) NQO2MTNR1AMTNR1BCYP19A1CYP11B2
SCHEMBL31660589 0.85 NQO2 (0.46) NQO2MTNR1AMTNR1BBRD4LMNA
SCHEMBL16473796 0.84 ESR2 (0.47) NQO2MTNR1AMTNR1BCYP19A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1805158-B1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS INC (US) 2018-06-27 EP disclosed
US-7915253-B2 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury KALYPSYS, INC (US) 2011-03-29 US disclosed
US-7834004-B2 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC (US) 2010-11-16 US disclosed
US-20090264417-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-10-22 US disclosed
US-20090227599-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-09-10 US disclosed
US-7517884-B2 {5-[4-(4-Trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-indan-2-yl}-acetic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury, diabetes KALYPSYS INC. (US) 2009-04-14 US disclosed
US-7494999-B2 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC (US) 2009-02-24 US disclosed
US-20090029971-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-01-29 US disclosed
US-20060205736-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC. 2006-09-14 US disclosed
US-20060167012-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC. 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167012-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR PPARG, PPARA, PPARD NQO2 2009/4885MTNR1A 160/4885MTNR1B 94/4885
US-20090029971-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD NQO2 2009/4885MTNR1A 160/4885MTNR1B 94/4885
US-20090227599-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD NQO2 2009/4885MTNR1A 160/4885MTNR1B 94/4885
US-20060205736-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR PPARG, PPARA, PPARD NQO2 2009/4885MTNR1A 160/4885MTNR1B 94/4885
US-20090264417-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD NQO2 2009/4885MTNR1A 160/4885MTNR1B 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.